Skip to main content
. 2022 Jun 6;13:3130. doi: 10.1038/s41467-022-30868-6

Fig. 6. CGRP as a mediator for BP-lowering effects of PRATA.

Fig. 6

a, b Serum or plasma levels of CGRP assessed by ELISA post PRATA in chronic (a) or acute (b) experiments. n = 11 for WKY-PRATA-4wk group, n = 14 for other groups in (a). n = 10 per group in (b); Data are mean ± SEM. P > 0.05 non-significant (ns), *P < 0.05, **P < 0.01, ***P < 0.001. ANOVA, Bonferroni post-hoc test, two-sided. c mRNA levels of CGRP assessed by qPCR in L1 and L2 DRGs post PRATA, n = 6 per group; Data are mean ± SEM, P > 0.05 non-significant (ns), *P < 0.05, **P < 0.01. ANOVA, Bonferroni post-hoc test, two-sided. d Changes of the intracarotid arterial MAP post PRATA combined with CGRP8-37 (1 mg/kg) treatment, n = 5 for WKY-Saline, WKY-CGRP8-37, SHR-PRATA-Saline groups, n = 6 for SHR-Saline, SHR-CGRP8-37, SHR-PRATA-CGRP8-37 groups; Data are mean ± SEM. *P < 0.05, WKY-Saline vs. WKY-CGRP8-37; #P < 0.05, SHR-PRATA-Saline vs. SHR-PRATA-CGRP8-37; P > 0.05 non-significant (ns), SHR-Saline vs. SHR-CGRP8-37. ANOVA, Bonferroni post-hoc test, two-sided. e Weekly measurement of tail arterial BP post PRATA combined with CGRP8-37 (10 μg/kg/d) treatment, n = 8 for WKY-CGRP8-37 group, n = 7 for other groups; Data are mean ± SEM. *P < 0.05, WKY-Saline vs. WKY-CGRP8-37; #P < 0.05, SHR-PRATA-Saline vs. SHR-PRATA-CGRP8-37; &P < 0.05, SHR-Saline vs. SHR-PRATA-CGRP8-37. ANOVA, Bonferroni post-hoc test, two-sided.